GlassScriptPhysician profile
Sharon D Jackson
NPI 1447799390
$13,057.15
in general payments reported to CMS, 2019-2025
41 companies · $2,402 in 2025
The $2,402 reported for 2025 was more than what 96% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,629 · 2022: $2,397 · 2023: $2,822 · 2024: $2,808 · 2025: $2,402.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,031.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,030.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,037.04 | 2021-2025 | |
| Glaxosmithkline, LLC. | $1,590.75 | 2021-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Lilly USA, LLC | $1,304.76 | 2021-2025 | Mounjaro, Zepbound, Trulicity |
| Astrazeneca Pharmaceuticals LP | $909.26 | 2021-2025 | Breztri, Farxiga, Airsupra |
| Pfizer INC. | $905.49 | 2023-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $767.44 | 2021-2025 | |
| Scilex Pharmaceuticals INC. | $736.11 | 2021-2025 | Ztlido |
| Novo Nordisk INC | $671.00 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Dexcom, INC. | $500.07 | 2021-2025 | Dexcom G6 Transmitter, Dexcom G7 Gss (161) |
| Ardelyx, INC. | $364.48 | 2023-2025 | Ibsrela |
| Boehringer Ingelheim Pharmaceuticals, INC. | $345.15 | 2021-2025 | Jardiance |
| Ironwood Pharmaceuticals, INC | $297.78 | 2022-2024 | Linzess |
| Biohaven Pharmaceutical Holding Company LTD. | $278.09 | 2022 | |
| Corcept Therapeutics | $274.00 | 2022-2025 | Korlym |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $212.26 | 2021-2024 | Trulance, Xifaxan |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sharon Jackson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.